Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of tesamorelin injection in China. Welcome to wholesale bulk high quality tesamorelin injection for sale here from our factory. Good service and reasonable price are available.
Tesamorelin Injection is an artificially synthesized growth hormone releasing hormone (GHRH) analog primarily used to treat lipid metabolism abnormalities under specific medical conditions. It stimulates the pituitary gland to release growth hormone (GH), thereby regulating fat metabolism, promoting protein synthesis, and affecting bone and muscle growth. Similar in structure to natural GHRH, but optimized to enhance stability and biological activity, prolonging half-life in vivo. It is injected subcutaneously (usually in the abdomen or thigh) and must strictly follow medical advice. Generally once a day, the specific dosage is adjusted by the doctor according to the patient's condition.
Our products
Tesamorelin COA
The 29 amino acid sequence of Tesamorelin leads to the accumulation of by-products (such as missing peptides)
Tesamorelin Injection is an artificially synthesized growth hormone releasing hormone (GHRH) analog, with a core active ingredient consisting of 29 amino acids. By simulating the physiological function of natural GHRH, it stimulates the pituitary gland to release growth hormone (GH), thereby regulating fat metabolism, protein synthesis, and bone growth.
Amino acid sequence characteristics and byproduct risks of Tesamorelin
Sequence Structure and Functional Key Sites
The amino acid sequence of Tesamorelin is: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH ₂
This sequence is optimized based on the 1-29 amino acids of natural human GHRH (1-44), achieving high efficiency and stability through the following design:
N-terminal modification: Addition of tyrosine (Tyr) at the head end to enhance receptor binding affinity.
C-terminal amidation: The terminal arginine (Arg) amidation (NH ₂) can prevent enzymatic hydrolysis and prolong half-life.
Key sites: 8th (Ser), 12th (Arg), 22nd (Leu) and other sites are crucial for GH release activity.
However, the sequence complexity of long-chain peptides, such as alternating hydrophobic/hydrophilic regions and repeating amino acids, may increase the synthesis error rate and the risk of byproduct formation.
Definition and classification of by-products
By products refer to impurities in the drug other than the target molecule, which mainly include:
Missing peptide: a sequence truncation caused by unsuccessful coupling of amino acids during synthesis (such as missing 1-2 amino acids).
Oxidation products: Sites containing methionine (Met) or tryptophan (Trp) are easily oxidized.
Dimer/Polymer: Peptide chains polymerize through non covalent or disulfide bonds.
Chemical degradation products: such as hydrolysis, deamidation, etc.
Among them, the missing peptide is the most common byproduct, and its formation is closely related to the easily breakable sites in the sequence (such as hydrophobic regions, Pro or Cys vicinity).
The formation mechanism of missing peptides in synthetic processes
Limitations of Solid Phase Peptide Synthesis (SPPS)
Tesamorelin is mainly prepared by Fmoc/tBu solid-phase synthesis method, which includes: resin loading of the first amino acid (starting from the C-terminus); Gradually deprotection and coupling to the next amino acid; Finally, cut and purify from the resin.
The main sources of missing peptides are:
Insufficient coupling efficiency: Some amino acids (such as Arg, His) fail to couple due to steric hindrance or charge repulsion, resulting in N-terminal deletion peptides.
Incomplete deprotection: Residual protective groups (such as Fmoc) may hinder subsequent conjugation and generate C-terminal deletion peptides.
Resin expansion/contraction: Physical changes in the resin during the synthesis process may lead to uneven local reactions and increase the probability of missing parts.
Sequence specific risk factors
Among the 29 amino acids in Tesamorelin, the following lower positions are prone to deletion:
14th position (Gly) and 15th position (Gln): Gly lacks side chains and has high spatial flexibility, which may lead to misalignment of coupling sites.
20th (Arg) and 21st (Lys): Strong alkaline side chains may cause charge repulsion and reduce coupling efficiency.
25th (Ile) and 26th (Met): Hydrophobic amino acids tend to aggregate, hindering solvation and reactant contact.
Accumulation of by-products in storage and stability
Physical degradation pathways
Tesamorelin Injection is a freeze-dried powder injection and should be stored in the dark at 2-8 ℃. During the storage process, there may be:
Moisture absorption: Moisture penetration causes hydrolysis of peptide chains, resulting in the formation of missing peptides (such as C-terminal truncation).
Temperature fluctuations: Repeated freezing and thawing may damage the secondary structure of peptide chains and increase the risk of oxidation.
Light exposure: Ultraviolet light induces the oxidation of methionine (Met26) to methionine sulfoxide (Met SO), further triggering chain breakage.
Chemical degradation mechanism
Deamidation: Asparagine (Asn8) is prone to deamidation under alkaline conditions, resulting in the formation of aspartic acid (Asp), which may be accompanied by peptide bond cleavage.
β - elimination: Sites containing Cys or Ser may undergo β - elimination reactions under alkaline conditions, leading to side chain loss and peptide chain truncation.
Disulfide bond exchange: If cysteine (Cys) is present in the sequence, it may form incorrect disulfide bonds, leading to polymerization or deletion.
The generation and impact of by-products in internal metabolism
Enzymatic hydrolysis and formation of missing peptides
Tesamorelin is mainly degraded in vivo by proteases such as DPP-IV and NEP
DPP-IV: The peptide bond that preferentially cleaves the N-terminal second proline (Pro) or alanine (Ala). The second position of Tesamorelin is Ala, which may be cleaved by DPP-IV to generate N-terminal deletion peptides (Tyr deletion).
NEP: The peptide bond formed by cleaving hydrophobic amino acids (such as Phe and Leu) may result in the deletion of the central sequence.
Animal experiments: After injection of Tesamorelin into rats, multiple missing peptides were detected in the plasma, among which Tyr Ala Asp Ala Ile Phe (positions 1-6) and Arg Lys Val Leu Gly (positions 12-16) had the highest proportion, indicating site selectivity of enzymatic hydrolysis in vivo.
Pharmacological and toxic effects of by-products
Reduced therapeutic effect: Missing peptides may lack key functional sites (such as GH releasing active domains), competitively bind to receptors but have no biological effects.
Immunogenic risk: New epitopes (such as hidden sequences exposed by missing peptides) may be recognized by the immune system, leading to antibody production.
Unknown side effects: Some missing peptides may have unexpected activity (such as pro-inflammatory or anti metabolic effects) and require long-term monitoring.
By product control and optimization strategies
Optimization of synthesis process
Amino acid coupling optimization: Use more efficient coupling reagents (such as HATU, COMU) to improve reaction efficiency. Adopting the "pseudo proline dipeptide" strategy for difficult to couple sites (such as Arg and Lys) to reduce steric hindrance.
Purification technology upgrade: Adopting reverse phase HPLC (RP-HPLC) combined with ion exchange chromatography (IEC) multi-stage purification to remove missing peptides to<0.5%. Introduce the quality oriented preparation (QbD) concept and monitor key quality attributes (CQAs) in real-time.
Formulation improvement
Stabilizer addition: Add freeze-drying protectants such as sucrose and mannitol to reduce peptide chain hydrolysis during storage. Use EDTA to chelate metal ions and inhibit oxidation reactions.
Packaging innovation: Adopting double chamber bag packaging to isolate drugs and solvents until they are mixed before use, reducing the risk of moisture absorption.
Structural Modification and Alternative Solutions
Introduction of non natural amino acids: Replace easily degradable sites (such as Asn8 → D-Asn) with D-type amino acids to improve stability.
Cyclization strategy: Cyclize the peptide chain through disulfide or amide bonds to reduce enzymatic hydrolysis sites (such as positions 8-12).
PEGylation: Connecting PEG molecules at the N-terminus or C-terminus of peptide chains to prolong half-life and reduce enzymatic hydrolysis.
The mechanism of action of Tesamorelin
Receptor binding and activation
Target: Tesamorelin Injection specifically binds to GHRH-R (a G protein coupled receptor, GPCR).
Binding process: The N-terminus of Tesamorelin (especially Tyr ¹ and Arg ¹ ²) is inserted into the transmembrane binding pocket of GHRH-R. The conformational change of the receptor activates the G α s protein coupled to it. The G α s protein activates adenylate cyclase (AC), catalyzing the generation of cyclic adenosine monophosphate (cAMP) from ATP.
Intracellular signal transduction
CAMP PKA pathway: cAMP acts as a second messenger, activating protein kinase A (PKA). PKA phosphorylates downstream target proteins (such as CREB) to promote GH gene transcription.
Calcium ion (Ca ² ⁺) signaling: receptor activation simultaneously triggers intracellular Ca ² ⁺ release, enhancing the immediacy of GH secretion.
GH synthesis and release: long-term effect: upregulate GH mRNA expression and increase GH synthesis reserve. Short term effect: Promote the rapid release of GH stored in secretory granules.
Antagonistic effect with somatostatin
Physiological balance: The hypothalamus simultaneously secretes somatostatin, which inhibits GH release.
The net effect of Tesamorelin: By continuously activating GHRH-R, Tesamorelin can partially overcome the inhibitory effect of somatostatin, especially restoring GH secretion rhythm in pathological states such as HIV related lipid metabolism disorders.
Protecting cellular function and delaying the aging process
Antioxidant stress: During the aging process, the level of oxidative stress in cells increases, leading to cell damage and functional impairment. GH and IGF-1 have antioxidant properties, which can alleviate oxidative stress damage to cells and protect them from age-related damage.
Promoting cell repair and regeneration: GH and IGF-1 can also promote cell repair and regeneration, helping to maintain the normal structure and function of organs. This is of great significance for delaying organ aging and maintaining organ function.
Potential intervention effects targeting specific organs
Liver: The liver is an important organ for metabolism, and its function gradually declines during the aging process. Tesamorelin helps improve liver metabolic function, reduce liver burden, and delay liver aging by regulating the secretion of GH and IGF-1.
Cardiovascular system: The cardiovascular system is one of the organs that are easily affected during the aging process. Tesamorelin can help reduce the risk of cardiovascular disease and protect cardiovascular health by improving fat metabolism and reducing visceral fat accumulation.
Musculoskeletal system: The aging of the musculoskeletal system is characterized by muscle atrophy, osteoporosis, and other symptoms. GH and IGF-1 play important roles in the growth and development of muscles and bones. Tesamorelin helps maintain the normal function of the musculoskeletal system and delay the aging process by promoting the secretion of GH and IGF-1.
Hot Tags: tesamorelin injection, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale